02-06-2020 13:43
via
pmlive.com
Pfizer’s Ibrance misses the mark in early breast cancer
Drug was unable to demonstrate statistical significance in primary endpoint
Read more »
Pharmaceutical Industry news
Antibiotics Not Helpful for Cough Due to Lower Respiratory Tract Infection
Hypertensive Disorders of Pregnancy Raise Risk for Postpartum Mortality for One Year
Most Moms-to-Be Interested in RSV Vaccination During Pregnancy
COVID-19 Treatment Guidelines Show Great Global Variance
Differences ID'd in Tau Burden in Down Syndrome, Alzheimer Disease
Impaired Fecundity Rate in Women Unchanged From 2011 to 2019
Exa-Cel Eliminates Vaso-Occlusive Crises in Most Sickle Cell Patients
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
Occurrence of Low-Birth-Weight Babies Heightened in Active-Duty Servicewomen
GLP1 Receptor Agonists Do Not Up Risk for Complications After Emergency Surgery
AI Model Reduces False Positives in Screening Mammograms
Prenatal Opioid Exposure Not Tied to Neuropsychiatric Disorders in Offspring
Tobacco Smoking Reduces the Odds of Psoriasis Improvement
Mortality Up for Breast Cancer Diagnosed Within 10 Years of Childbirth
Desktop versie